Citius Oncology (CTOR) Non-Current Assets (2022 - 2026)

Citius Oncology (CTOR) has 5 years of Non-Current Assets data on file, last reported at $71.3 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 2.89% year-over-year to $71.3 million in Q1 2026; TTM through Mar 2026 was $290.9 million, a 8.0% increase from a year earlier, with the FY2025 full-year figure at $73.4 million, changed 0.0% from the prior year.
• Non-Current Assets for Q1 2026 stood at $71.3 million, down from $72.8 million in the prior quarter.
• Over the last five years, Non-Current Assets for CTOR reached as high as $73.4 million in Q3 2024 and fell as low as $40.0 million in Q3 2023.
• Historically, Non-Current Assets has averaged $66.2 million across 5 years, with a median of $71.9 million in 2023.
• On a YoY basis, Non-Current Assets climbed as much as 83.5% in 2024 and fell as far as 29.16% in 2024.
• Year by year, Non-Current Assets stood at $67.8 million in 2022, then increased by 7.01% to $72.6 million in 2023, then increased by 1.15% to $73.4 million in 2024, then declined by 0.78% to $72.8 million in 2025, then fell by 2.13% to $71.3 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $71.3 million in Q1 2026, $72.8 million in Q4 2025, and $73.4 million in Q3 2025.